Further resources

14 March 2018

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Rosenstock J et al. Cardiovasc Diabetol 2018;17:39

[https://cardiab.biomedcentral.com/articles/10.1186/s12933-018-0682-3]

©2019 Boehringer Ingelheim International GmbH. All rights reserved.